Ken Griffin
AVDL

Ken Griffin’s Avadel Pharmaceuticals AVDL Stock Holding History

Ken Griffin’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-770,232
Closed -$16.6M – 12954
2025
Q4 		$16.6M Sell
770,232
-287,654
-27% -$5.58M ﹤0.01% 2588
2025
Q3 		$16.2M Sell
1,057,886
-470,431
-31% -$6.12M ﹤0.01% 2599
2025
Q2 		$13.5M Sell
1,528,317
-716,693
-32% -$6.3M ﹤0.01% 2640
2025
Q1 		$17.6M Sell
2,245,010
-348,528
-13% -$2.92M ﹤0.01% 2188
2024
Q4 		$27.3M Buy
2,593,538
+234,992
+10% +$2.85M ﹤0.01% 1840
2024
Q3 		$30.9M Buy
2,358,546
+117,265
+5% +$1.79M 0.01% 1653
2024
Q2 		$31.5M Buy
2,241,281
+677,391
+43% +$11M 0.01% 1566
2024
Q1 		$26.4M Buy
1,563,890
+950,705
+155% +$14.2M 0.01% 1796
2023
Q4 		$8.66M Buy
613,185
+150,080
+32% +$1.76M ﹤0.01% 3042
2023
Q3 		$4.77M Sell
463,105
-23,090
-5% -$309K ﹤0.01% 3721
2023
Q2 		$8.01M Buy
486,195
+167,714
+53% +$2.18M ﹤0.01% 2971
2023
Q1 		$2.92M Buy
318,481
+218,484
+218% +$1.8M ﹤0.01% 4678
2022
Q4 		$716K Buy
99,997
+10,677
+12% +$74.9K ﹤0.01% 7493
2022
Q3 		$447K Sell
89,320
-71,742
-45% -$395K ﹤0.01% 8709
2022
Q2 		$393K Buy
161,062
+74,365
+86% +$305K ﹤0.01% 9172
2022
Q1 		$592K Sell
86,697
-34,679
-29% -$238K ﹤0.01% 8986
2021
Q4 		$981K Buy
121,376
+32,589
+37% +$298K ﹤0.01% 8007
2021
Q3 		$870K Sell
88,787
-25,522
-22% -$201K ﹤0.01% 8497
2021
Q2 		$770K Buy
114,309
+1,142
+1% +$9.07K ﹤0.01% 9044
2021
Q1 		$1.02M Buy
113,167
+24,456
+28% +$198K ﹤0.01% 8051
2020
Q4 		$593K Buy
88,711
+16,791
+23% +$105K ﹤0.01% 7832
2020
Q3 		$363K Buy
71,920
+21,947
+44% +$160K ﹤0.01% 7815
2020
Q2 		$404K Buy
49,973
+30,759
+160% +$271K ﹤0.01% 7436
2020
Q1 		$153K Sell
19,214
-118,144
-86% -$907K ﹤0.01% 8275
2019
Q4 		$1.04M Buy
137,358
+111,422
+430% +$589K ﹤0.01% 5511
2019
Q3 		$107K Sell
25,936
-6,367
-20% -$15.9K ﹤0.01% 8455
2019
Q2 		$93K Buy
+32,303
New +$55.5K ﹤0.01% 8553
2019
Q1 		– Sell
-96,885
Closed -$250K – 9235
2018
Q4 		$250K Sell
96,885
-24,455
-20% -$83.2K ﹤0.01% 7543
2018
Q3 		$533K Sell
121,340
-128,751
-51% -$695K ﹤0.01% 6590
2018
Q2 		$1.53M Buy
250,091
+129,340
+107% +$907K ﹤0.01% 4506
2018
Q1 		$880K Sell
120,751
-27,924
-19% -$246K ﹤0.01% 5016
2017
Q4 		$1.22M Buy
148,675
+53,606
+56% +$503K ﹤0.01% 4369
2017
Q3 		$998K Buy
95,069
+62,989
+196% +$601K ﹤0.01% 4328
2017
Q2 		$354K Buy
+32,080
New +$322K ﹤0.01% 5628
2017
Q1 		– Sell
-13,643
Closed -$142K – 7416
2016
Q4 		$142K Buy
13,643
+3,220
+31% +$35.4K ﹤0.01% 6532
2016
Q3 		$129K Buy
+10,423
New +$136K ﹤0.01% 6548
2016
Q1 		– Sell
-12,995
Closed -$159K – 6755
2015
Q4 		$159K Buy
+12,995
New +$203K ﹤0.01% 6118
2015
Q2 		– Sell
-17,865
Closed -$321K – 8710
2015
Q1 		$321K Buy
17,865
+6,766
+61% +$106K ﹤0.01% 5555
2014
Q4 		$190K Buy
+11,099
New +$158K ﹤0.01% 6028

Other funds holding AVDL

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Ken Griffin's AVDL Position: Q1 2026 in Review

Ken Griffin sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 770,232 shares — an estimated $16.6M sold.

Ken Griffin first reported a position in AVDL in Q4 2014 and held it in 39 quarters. The position peaked at $31.5M in Q2 2024. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

  • Ken Griffin reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Ken Griffin sold 770,232 Avadel Pharmaceuticals shares in Q1 2026, an estimated $16.6M.
  • Ken Griffin first reported a position in Avadel Pharmaceuticals in Q4 2014 and held it in 39 quarters.
  • Ken Griffin's Avadel Pharmaceuticals position peaked at $31.5M in Q2 2024.
  • 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.